These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7750051)

  • 1. Pixel or death: experience from clinical trials assessing lipid lowering therapy.
    Barth JD
    Can J Cardiol; 1995 May; 11 Suppl C():9C-14C. PubMed ID: 7750051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoproteins and the progression/regression of atherosclerosis.
    Barth JD
    Baillieres Clin Endocrinol Metab; 1995 Oct; 9(4):849-66. PubMed ID: 8593128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
    Hodis HN
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.
    Brown BG; Zhao XQ; Sacco DE; Albers JJ
    Circulation; 1993 Jun; 87(6):1781-91. PubMed ID: 8504494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The relationship between clinical events and the angiographic lesions in coronary atherosclerosis. Hypolipemic treatment and plaque stabilization].
    Castro Beiras A; Vázquez Rodríguez JM; Muñiz J; Calviño R; Vázquez González N; Juane R
    Rev Esp Cardiol; 1995; 48 Suppl 5():23-30. PubMed ID: 7494936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of severe atherosclerotic plaque in patients with mild elevation of LDL cholesterol.
    Schaefer S; Hussein H; Gershony GR; Rutledge JC; Kappagoda CT
    J Investig Med; 1997 Dec; 45(9):536-41. PubMed ID: 9444880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiographic trials of lipid-lowering therapy: an update.
    Mancini GB
    Curr Opin Lipidol; 1995 Dec; 6(6):379-85. PubMed ID: 8750252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia in patients with angiographically confirmed coronary artery disease--an opportunity for improvement.
    Khanal S; Obeidat O; Lu M; Douthat L; Hudson MP; Greenbaum AB; Kugelmass A; Weaver WD
    Clin Cardiol; 2004 Oct; 27(10):577-80. PubMed ID: 15553311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms underlying reduction of clinical events in lipid lowering trials.
    Mancini GB
    Can J Cardiol; 1995 May; 11 Suppl C():15C-17C. PubMed ID: 7750043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipid factors and evolution of the atherosclerotic plaque: review of recent trials].
    Scardi S
    G Ital Cardiol; 1996 Dec; 26(12):1481-93. PubMed ID: 9162677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we cause regression of coronary atherosclerosis?
    Alsafwah S; Ramanathan KB
    Am J Med Sci; 2008 May; 335(5):368-74. PubMed ID: 18480653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
    Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different impacts of C-reactive protein and lipid profile on coronary lesions following a percutaneous coronary intervention.
    Xu HY; Qiao SB; Zhang JF; Dong QT; Li JJ
    Coron Artery Dis; 2012 May; 23(3):181-7. PubMed ID: 22336660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.